An investigation into the effect of concurrent training and Q10 supplementation on diabetes

The effect of a concurrent training period along with Q10 supplementation on the symptoms of diabetic neuropathy, and some inflammatory and antioxidant parameters in patients with type 2 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20241029063535N2

Enrollment

Registered

2025-11-16

Start date

2025-03-21

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes. Type 2 diabetes mellitus

Interventions

Intervention 1: Control group: Participants in the control group received identical capsules containing starch powder. Intervention 2: Intervention group 1: Exercise + Q10 supplement group. This group

Eligibility

Sex/Gender

Male

Age

25 Years to 45 Years

Inclusion criteria

Inclusion criteria: Willingness to participate in the study Male with type 2 diabetes Age range: 25-45 years No use of any dietary supplements or specific medications in the past 3 months No history of participation in a regular exercise program during the previous 6 months, Ability to perform resistance training with free weights, and aerobic exercises (including walking)

Exclusion criteria

Exclusion criteria: Presence of acute or severe chronic diseases (e.g., heart failure, advanced kidney disease, liver diseases) History of recent cardiovascular events (myocardial infarction or stroke within the past 6 months) Diagnosis of active inflammatory or autoimmune diseases Regular use of anti-inflammatory medications or corticosteroids Presence of musculoskeletal disorders that prevent participation in exercise training History of alcohol or substance abuse Concurrent participation in other research studies

Design outcomes

Primary

Measure	Time frame
Neuropathy Score in Toronto Clinical Neuropathy Scale (TCNS). Timepoint: At baseline and after 8 weeks of intervention. Method of measurement: Toronto Clinical Neuropathy Score.	—

Secondary

Measure	Time frame
Serum Interleukin-6 Concentration. Timepoint: At baseline and after 8 weeks of intervention. Method of measurement: Serum interleukin-6 level was measured using ELISA kit from R&D Systems (Code: D6050).;Serum Malondialdehyde (MDA) Concentration. Timepoint: At baseline and after 8 weeks of intervention. Method of measurement: Serum malondialdehyde (MDA) level was measured using commercial kit from ZellBio GmbH, Germany.	—

Measure

Time frame

Serum Interleukin-6 Concentration. Timepoint: At baseline and after 8 weeks of intervention. Method of measurement: Serum interleukin-6 level was measured using ELISA kit from R&D Systems (Code: D6050).;Serum Malondialdehyde (MDA) Concentration. Timepoint: At baseline and after 8 weeks of intervention. Method of measurement: Serum malondialdehyde (MDA) level was measured using commercial kit from ZellBio GmbH, Germany.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHadi abdi

Payame Noor University

abdi.h@pnu.ac.ir+98 84 3333 7078

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026